BriaCell Therapeutics Corp. (BCTX)

NASDAQ: BCTX · IEX Real-Time Price · USD

0.790

+0.030 (3.95%)

At close: Jul 19, 2024, 4:00 PM

0.781

-0.010 (-1.20%)

Pre-market: Jul 22, 2024, 7:35 AM EDT

BriaCell Therapeutics Income Statement

Financials in millions USD. Fiscal year is August - July.

Millions USD. Fiscal year is Aug - Jul.

Year Ending	TTM	Jul 31, 2023	Jul 31, 2022	Jul 31, 2021	Jul 31, 2020	Jul 31, 2019	2018
Selling, General & Admin	7.33	7.94	7.27	4.96	1.16	0.78	Upgrade
Research & Development	27.94	15.34	8.02	2.02	1.87	3.08	Upgrade
Other Operating Expenses	0	0	0	0	0	0.04	Upgrade
Operating Expenses	35.27	23.27	15.29	6.98	3.03	3.9	Upgrade
Operating Income	-35.27	-23.27	-15.29	-6.98	-3.03	-3.9	Upgrade
Interest Expense / Income	-14.76	-2.97	11.55	6.84	0.02	0.02	Upgrade
Other Expense / Income	-14.47	-	-	-	0.04	-0.29	Upgrade
Pretax Income	-6.04	-20.3	-26.84	-13.82	-3.1	-3.63	Upgrade
Net Income	-6.04	-20.3	-26.84	-13.82	-3.1	-3.63	Upgrade
Shares Outstanding (Basic)	16	16	15	5	1	1	Upgrade
Shares Outstanding (Diluted)	16	16	15	5	1	1	Upgrade
Shares Change	2.99%	0.81%	242.82%	533.09%	23.16%	35.49%	Upgrade
EPS (Basic)	-0.37	-1.30	-1.73	-3.06	-4.34	-6.26	Upgrade
EPS (Diluted)	-1.25	-1.30	-1.73	-3.06	-4.34	-6.26	Upgrade
Free Cash Flow	-31.01	-23.74	-12.48	-7.75	-0.97	-3.19	Upgrade
Free Cash Flow Per Share	-1.94	-1.52	-0.81	-1.72	-1.36	-5.51	Upgrade
EBITDA	-20.78	-23.26	-15.27	-6.96	-3.06	-3.6	Upgrade
Depreciation & Amortization	0.02	0.02	0.02	0.02	0.01	0.01	Upgrade
EBIT	-20.8	-23.27	-15.29	-6.98	-3.08	-3.61	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).